Today, the CEO & Chief Scientific Officer of Amphastar Pharmaceuticals (NASDAQ: AMPH), Jack Zhang, bought shares of AMPH for $642.5K.
See today’s analyst top recommended stocks >>
Based on Amphastar Pharmaceuticals’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $58.39 million and GAAP net loss of $7.25 million. In comparison, last year the company earned revenue of $56.67 million and had a net profit of $893K. Currently, Amphastar Pharmaceuticals has an average volume of 204K.
Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $21.50, reflecting a -24.6% downside. Five different firms, including Jefferies and Needham, currently also have a Buy rating on the stock.
The insider sentiment on Amphastar Pharmaceuticals has been negative according to 60 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Jack Zhang’s trades have generated a 10.8% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments.
